QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme.

In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD… Poursuivre la lecture de QCMD to use RNAssist’s virusPHIX-P9™ Biomolecule Stabilization Technology in its SARS-CoV-2 antigen EQA scheme.